Literature DB >> 9802742

Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.

L Heinemann1, C Weyer, M Rauhaus, S Heinrichs, T Heise.   

Abstract

OBJECTIVE: To study the intra- and interindividual variability of the metabolic activity of soluble insulin and of the rapid-acting insulin analog insulin aspart after subcutaneous injection. RESEARCH DESIGN AND METHODS: A total of nine healthy male volunteers received subcutaneous injections of soluble insulin (0.2 U/kg) in the abdominal region on each of the four study days. Another 10 volunteers received an injection of insulin aspart four times. Glucose infusion rates necessary to neutralize the blood glucose-lowering effect of the administered insulin were registered during euglycemic glucose clamps (blood glucose 5.0 mmol/l; basal intravenous insulin infusion 0.15 mU x kg(-1) x min(-1) over the subsequent 600 min. We investigated the variation in metabolic activity by calculating coefficients of variation (CVs).
RESULTS: In comparison to soluble insulin, subcutaneous injections of insulin aspart led to a more rapid onset of action and a shorter duration of action. Subcutaneous injection of the insulin preparations resulted in intraindividual CVs of the summary measures between 10 and 30% (soluble insulin vs. insulin aspart: maximal metabolic activity 15+/-7 vs. 16+/-10%, time to maximal metabolic activity 14+/-10 vs. 11+/-6%; NS between the preparations [means +/- SD]). The decline to half-maximal activity after maximal activity showed a lower intraindividual CV with insulin aspart (19+/-9 vs. 11+/-5%; P = 0.018). The interindividual CVs were higher than the intraindividual CVs (26 vs. 28, 23 vs. 19, and 26 vs. 17%). Generally, the pharmacodynamic variability was higher than the pharmacokinetic variability. For the pharmacokinetic measures, the intra- and interindividual variability in t(max) was lower for insulin aspart than for soluble insulin.
CONCLUSIONS: The metabolic effect of soluble insulin shows an intraindividual variability of 10-20% in healthy volunteers, even under strictly controlled experimental conditions. The overall variability of action of insulin aspart was comparable to that of soluble insulin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802742     DOI: 10.2337/diacare.21.11.1910

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  36 in total

Review 1.  Can technological solutions for diabetes replace islet cell function?

Authors:  Justin M Gregory; Daniel J Moore
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

2.  Insulin pump basal adjustment for exercise in type 1 diabetes: a randomised crossover study.

Authors:  Sybil A McAuley; Jodie C Horsburgh; Glenn M Ward; André La Gerche; Judith L Gooley; Alicia J Jenkins; Richard J MacIsaac; David N O'Neal
Journal:  Diabetologia       Date:  2016-05-11       Impact factor: 10.122

Review 3.  Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.

Authors:  Israel Hartman
Journal:  Clin Med Res       Date:  2008-09-18

4.  Sources of glycemic variability--what type of technology is needed?

Authors:  Jonas Kildegaard; Toke Folke Christensen; Ole Kristian Hejlesen
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

5.  Use of a food and drug administration-approved type 1 diabetes mellitus simulator to evaluate and optimize a proportional-integral-derivative controller.

Authors:  Srinivas Laxminarayan; Jaques Reifman; Garry M Steil
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

Review 6.  Clinical pharmacokinetics and pharmacodynamics of insulin aspart.

Authors:  A Lindholm; L V Jacobsen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 7.  Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.

Authors:  Neil A Reynolds; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Differences in the dose accuracy of insulin pens.

Authors:  Heike Hänel; Alexander Weise; Wei Sun; Johannes W Pfützner; Nicole Thomé; Andreas Pfützner
Journal:  J Diabetes Sci Technol       Date:  2008-05

9.  A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: model structure and parameter identification.

Authors:  Jason Wong; J Geoffrey Chase; Christopher E Hann; Geoffrey M Shaw; Thomas F Lotz; Jessica Lin; Aaron J Le Compte
Journal:  J Diabetes Sci Technol       Date:  2008-07

Review 10.  Clinical pharmacokinetics and pharmacodynamics of inhaled insulin.

Authors:  John S Patton; Julie G Bukar; Michael A Eldon
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.